Amgen ($AMGN) announced Phase 3 trial results showing that combining Imdelltra with Imfinzi reduced the risk of death by 58% in patients with small-cell lung cancer, compared with Imfinzi alone.…
Anonymous readers can preview up to 1024 characters here. Log in to unlock the full article once ingest succeeds.